Olivier Barret

Olivier Barret

Auto-generated profile, based on publicly available information

Olivier Barret

Institute for Neurodegenerative Disorders, New Haven, CT 06510, USA

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2020 in JAMA Neurology
Verified
Journal Article
Closed access
PDF file
MBMatthias Brendel
Matthias Brendel
HBHenryk Barthel
Henryk Barthel
TEThilo van Eimeren
Thilo van Eimeren
KMKen Marek
Ken Marek
LBLeonie Beyer
Leonie Beyer
OSOsama Sabri
Osama Sabri
Progressive supranuclear palsy (PSP), initially described by Steele et al,1 is a primary 4-repeat tauopathy2 clinically characterized by postural instability with falls and impaired volitional eye movements and leading to death with a median of 8 years after symptom onset.2 However, clinical symptoms and subtypes of PSP also have strong overlaps with other neurodegenerative disorders such as TDP-43–positive frontotemporal dementia or corticobasal degeneration.3,4 Thus, clinical assessments in PSP are lacking sensitivity early in the disease course and have a limited specificity for the pathologic entity.5 Therefore, biomarkers for PSP have a great range of potential utility, for which formal criteria are now available.6 Current PSP diagnosis criteria already take imaging of atrophy or hypometabolism by magnetic resonance imaging or positron emission tomography (PET) into account.5 However, no available biomarker currently fulfills the criteria for an ideal biomarker, which would be positive in a presymptomatic stage, specific for any variant of pathology, and anticipate disease progression.6 As more established readouts (hypometabolism, atrophy) represent late events in the disease course, tau-PET imaging may be able to provide more favorable biomarker information for early detection of PSP. Other tau-PET tracers were reported to be able to differentiate patients with PSP from controls,7-9 but the observed binding was not confirmed to specifically relate to tau.10-12 The novel tau-PET tracer 18F-PI-2620 proved absent off-target binding to monoamine oxidases,13 high affinity to 3/4R tau in Alzheimer disease (AD),14 but also high affinity to recombinant 4R tau fibrils and PSP brain homogenate,13 and colocalized binding to proven 4R tau by a combination of micro-autoradiography and immunohistochemistry in PSP tissue.13

11 November 2019 in Journal of Nuclear Medicine
Verified
Journal Article
Closed access
PDF file
AMAndre Mueller
Andre Mueller
SBSantiago Bullich
Santiago Bullich
OBOlivier Barret
Olivier Barret
JMJennifer Madonia
Jennifer Madonia
MBMathias Berndt
Mathias Berndt
ASAndrew W. Stephens
Andrew W. Stephens
18F-PI-2620 is a PET tracer with high binding affinity for aggregated tau, a key pathologic feature of Alzheimer disease (AD) and other neurodegenerative disorders. Preclinically, 18F-PI-2620 binds to both 3-repeat and 4-repeat tau isoforms. The purpose of this first-in-humans study was to evaluate the ability of 18F-PI-2620 to detect tau pathology in AD patients using PET imaging, as well as to assess the safety and tolerability of this new tau PET tracer. Methods: Participants with a clinical diagnosis of probable AD and healthy controls (HCs) underwent dynamic 18F-PI-2620 PET imaging for 180 min. 18F-PI-2620 binding was assessed visually and quantitatively using distribution volume ratios (DVR) estimated from noninvasive tracer kinetics and SUV ratio (SUVR) measured at different time points after injection, with the cerebellar cortex as the reference region. Time–activity curves and SUVR were assessed in AD and HC subjects, as well as DVR and SUVR correlations and effect size (Cohen’s d) over time. Results:18F-PI-2620 showed peak brain uptake around 5 min after injection and fast washout from nontarget regions. In AD subjects, focal asymmetric uptake was evident in temporal and parietal lobes, precuneus, and posterior cingulate cortex. DVR and SUVR in these regions were significantly higher in AD subjects than in HCs. Very low background signal was observed in HCs. 18F-PI-2620 administration was safe and well tolerated. SUVR time–activity curves in most regions and subjects achieved a secular equilibrium after 40 min after injection. A strong correlation (R2 > 0.93) was found between noninvasive DVR and SUVR for all imaging windows starting at more than 30 min after injection. Similar effect sizes between AD and HC groups were obtained across the different imaging windows. 18F-PI-2620 uptake in neocortical regions significantly correlated with the degree of cognitive impairment. Conclusion: Initial clinical data obtained in AD and HC subjects demonstrated a high image quality and excellent signal-to-noise ratio of 18F-PI-2620 PET for imaging tau deposition in AD subjects. Noninvasive quantification using DVR and SUVR for 30-min imaging windows between 30 and 90 min after injection—for example, 45–75 min—provides robust and significant discrimination between AD and HC subjects. 18F-PI-2620 uptake in expected regions correlates strongly with neurocognitive performance.

1 January 2021 in Parkinsonism & Related Disorders
Verified
Journal Article
Closed access
SLSonia Lavisse
Sonia Lavisse
SGSébastien Goutal
Sébastien Goutal
CWCatriona Wimberley
Catriona Wimberley
MTMattéo Tonietto
Mattéo Tonietto
MBMichel Bottlaender
Michel Bottlaender
PRPhilippe Remy
Philippe Remy

28 June 2019 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
SBSandra Sanabria Bohórquez
Sandra Sanabria Bohórquez
JMJan Marik
Jan Marik
AOAnnie Ogasawara
Annie Ogasawara
JTJeff N. Tinianow
Jeff N. Tinianow
HGHerman S. Gill
Herman S. Gill
RWRobby M. Weimer
Robby M. Weimer

3 October 2019 in Brain
Verified
Journal Article
Closed access
PDF file
YCYaping Chu
Yaping Chu
SMScott Muller
Scott Muller
ATAdriana Tavares
Adriana Tavares
OBOlivier Barret
Olivier Barret
DADavid Alagille
David Alagille
JKJeffrey H Kordower
Jeffrey H Kordower
Several studies have demonstrated that intrastriatal injections of fibrillar α-synuclein in rodent brain induced a Parkinson’s disease-like propagation of Lewy body pathology with significant nigrostriatal neurodegeneration. This study evaluated the pathological features when exogenous α-synuclein preformed fibrils were injected into the putamen of non-human primates. Eight cynomolgus monkeys received unilateral intraputamen injections of α-synuclein preformed fibrils and four monkeys received sham surgery. Monkeys were assessed with 123I-PE2I single-photon emission computerized tomography scans targeting the dopamine transprter at baseline, 3, 6, 9, 12, and 15 months. Imaging revealed a robust increase in dopamine transporter binding, an effect confirmed by port-mortem immunohistochemical analyses, suggesting that upregulation of dopamine transporter occurs as part of an early pathological process. Histochemistry and immunohistochemistry revealed that α-synuclein preformed fibrils injections into the putamen induced intraneuronal inclusions positive for phosphorylated α-synuclein in ipsilateral substantia nigra and adjacent to the injection site. α-Synuclein inclusions were thioflavin-S-positive suggesting that the inclusions induced by α-synuclein preformed fibrils exhibited pathological properties similar to amyloid-like Lewy body pathology in Parkinson’s disease brains. The α-synuclein preformed fibrils resulted in Lewy pathology in the ipsilateral substantia nigra with significant reduction (−29.30%) of dopaminergic neurons as compared with controls. Nigral neurons with α-synuclein inclusions exhibited a phenotypic downregulation of the dopamine markers tyrosine hydroxylase and Nurr1. Taken together, our findings demonstrate that α-synuclein preformed fibrils induce a synucleinopathy in non-human primates with authentic Lewy pathology and nigrostriatal changes indicative of early Parkinson’s disease.

1 December 2014 in JAMA Neurology
Verified
Journal Article
Closed access
PDF file
DRDavid S. Russell
David S. Russell
OBOlivier Barret
Olivier Barret
DJDanna L. Jennings
Danna L. Jennings
JFJoseph H. Friedman
Joseph H. Friedman
GTGilles D. Tamagnan
Gilles D. Tamagnan
KMKenneth L. Marek
Kenneth L. Marek
Research from JAMA Neurology — The Phosphodiesterase 10 Positron Emission Tomography Tracer, [18F]MNI-659, as a Novel Biomarker for Early Huntington Disease